Eli Lilly (NYSE: LLY) has achieved a major milestone by securing regulatory approval for its weight management drug, Mounjaro, in China. This development, confirmed through the company’s ...

Eli Lilly did not specify when sales of the drug would begin in China, or how many doses would be sold, according to Reuters. The drugmaker did not immediately respond to Investopedia 's request ...

Eli Lilly & Co.’s Mounjaro gained Chinese regulatory approval for weight less than a month after a similar therapy from Novo Nordisk A/S, fueling competition in a nation that’s among the world ...

SHANGHAI (Reuters) -Eli Lilly said in a social media post Friday its weight loss drug tirzepatide had received approval from Chinese regulators, further intensifying competition with its Danish ...

On Friday, China’s National Medical Products Administration (NMPA) approved Eli Lilly And Co (NYSE:LLY) Tirzepatide for long-term weight management. It is suitable for long-term weight ...

The move intensifies the competition with Eli Lilly, which secured approval for its weight-loss drug in China in July but has yet to launch it.

‘China’s Ozempic’ may vie with Eli Lilly, Novo Nordisk for global weight-loss drug market Drug manufacturers to focus on China and Japan, where penetration is low and innovation continues to ...

Eli Lilly (NYSE:LLY) received approval from the Hong Kong government to launch its weight-loss drug—Mounjaro, with sales expected to begin as early as year-end, Bloomberg reported.

Wegovy was marketed earlier than Zepbound, and is currently the world's best-selling GLP-1 weight loss medicine. Lilly said the trial results showed that on average, Zepbound led to a weight loss ...

Earlier on Wednesday, Laekna, "a global biotech company focused on novel drug development for metabolic and cancer diseases," accoding to its release, announced a clinical collaboration with Eli ...

Eli Lilly has won approval from Chinese regulators to sell its weight-loss treatment tirzepatide in the country, the company said in a social media post on Friday.

Eli Lilly said in a social media post Friday its weight loss drug tirzepatide had received approval from Chinese regulators, further intensifying competition with its Danish rival Novo Nordisk in ...